Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study
by Stacey
No Comments
among patients with COVID-19 that require treatment in intensive care for acute respiratory distress syndrome (ARDS), mortality has been reported between the 16 – 78% (1). In patients discharged alive, an increased risk of sequelae of anticipated COVID-19 (2). Hyperinflammatory response caused by SARS-CoV-2 is important in the pathogenesis COVID-19 and accompanied by a deregulated expression of interleukin 6 ( IL -6) were correlated with the severity of the disease (3 ).
Tocilizumab, monoclonal antibodies against IL -6 receptors originally licensed for use in rheumatoid arthritis, is also approved for the treatment of a chimeric antigen receptor T cell cytokine release syndrome-related and secondary hemophagocytic syndrome that shares important features with hyperinflammatory phase in COVID-19.
Several small studies from China and Europe have reported promising results of treatment with tocilizumab in patients with COVID-19, preventing the need for admission to intensive care units and improve clinical outcomes (4,5).
We aimed to evaluate the impact of treatment with tocilizumab compared with routine maintenance on important clinical outcomes in critically ill patients admitted to the intensive care unit with ARDS because COVID-19.
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study
Hand, foot, and mouth of the baby because of coxsackievirus A6 in Shanghai
Background: Evidence of hand, foot and mouth disease (HFMD) in neonates is limited. The purpose of this study was to evaluate clinical symptoms, pathogens, possible transmission route, and prognosis of neonatal HFMD in Shanghai.
Methods: This study is a case-control study based surveillance system registry HFMD. All neonates and infected family members were enrolled between 2016 and 2017 in Shanghai. Neonates with HFMD were followed for at least half a year. Detailed questionnaires, medical history, and physical examination were recorded. routine examination of blood, liver and kidney function, immunophenotypes peripheral blood lymphocytes (CD3, CD4, and CD8 T-cells, NK cells), immunoglobulin (Ig) M, IgG, and IgA, and cytokine interleukin (IL-1β, IL-2R , IL-6, IL-8, IL-10, and TNF-α) levels were measured.
All rectal swab specimens were collected and genotypes of enteroviruses, and phylogenetic analysis based on sequence VP1 of coxsackievirus A6 (CV-A6) was conducted to investigate the molecular characteristics and evolution. T-test or nonparametric test was used to evaluate the difference. logistic analysis was applied to calculate the risk of clinical manifestations in the neonatal group and their brother paired HFMD.
Results: There were 16 neonates among 12 608 patients diagnosed with HFMD, accounting for 0.13%. All neonatal infection transmitted by other family members, especially the older brother, and is caused by the CV-A6. CV-A6 is the causative agent appears and dominant of HFMD in Shanghai. None of neonates with HFMD has a fever, onychomadesis, or severe complications. However, two patients older brothers showed lethargy, and an advanced hypoperfusion.
In older brother with HFMD, the proportion of white blood cells is generally higher than in neonates with HFMD. Immunological function of neonates with HFMD basically normal. Higher levels of inflammatory markers in both neonates and older brother with HFMD compared with controls of the same age. Clinical symptoms subsided about 1 week after the onset. None of the neonates had sequelae.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Interleukin 16 (IL16) in samples from serum, plasma or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Interleukin 16 (IL16) in samples from serum, plasma or other biological fluids.
Description: Quantitativesandwich ELISA kit for measuring Rat Interleukin 16, IL-16 in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Rat Interleukin 16, IL-16 in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Conclusions: In our study, the CV-A6 infection in neonates are benign, but it has the character of a family grouping. Because the two-child policy in China, the elder brother may be the main route of transmission of HFMD.
